Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension of UX003 in MPS 7
NCT02432144Phase 3Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Nov 2015
- Primary completion
- Jan 2019
- Modality
- Replacement Enzymes
- Countries
- 4
01
Overview
A Phase 3 trial of vestronidase alfa in mucopolysaccharidosis type VII, sponsored by Ultragenyx Pharmaceutical Inc.. Started Nov 2015; status: completed.
02
Drugs
vestronidase alfa
03
Conditions
mucopolysaccharidosis type VII
Beyond the preview
Go deeper on NCT02432144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432144.